Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex to Present at the Jefferies 2021 Virtual Healthcare Conference

Nes Ziona, Israel, June 03, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
June 01, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy

Nes-Ziona, Israel, June 01, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
May 18, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis

Grant provides $1.1 million in non-dilutive funding for 2021 Nes Ziona, Israel, May 18, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage...
April 08, 2021 20:00 ET | Source: DelveInsight Business Research LLP

Promising Treatment for Sepsis Enters Clinical Trials: A Pipeline Products Review by DelveInsight

Los Angeles, USA , April 08, 2021 (GLOBE NEWSWIRE) -- Promising Treatment for Sepsis Enters Clinical Trials: A Pipeline Products Review by DelveInsight The Sepsis pipeline is robust, with...
March 22, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors

Nes Ziona, Israel, March 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting...
March 09, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex Announces Upcoming Virtual Investor Conference Participations

Nes Ziona, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
March 08, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T Therapies

Nes-Ziona, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
March 01, 2021 07:55 ET | Source: Enlivex Therapeutics Ltd

Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors

-- Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor...
February 22, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy

Nes-Ziona, Israel, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
February 18, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares

Nes Ziona, Israel, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in...